COMPASS Pathways (NASDAQ:CMPS) saw its stock soar by 23.06% to $7.15 during Tuesday’s premarket trading session, igniting chatter on the floor. This frenzy followed the announcement that they hit the primary endpoint in their Phase 3 COMP006 trial targeting treatment-resistant depression—a space crying out for effective solutions.
Depression Data: The Numbers Game
Breaking down the stats, in the 25 mg dose group of COMP360, a notable reduction in symptom severity emerged compared to the placebo arm. Specifically, they reported a mean difference of -3.8 between doses (25 mg versus 1 mg), with a p-value of